| 词条 | Estradiol valerate/norethisterone enantate |
| 释义 |
| image = Estradiol valerate.svg | width = 250px | caption = | image2 = Norethindrone enanthate.svg | width2 = 250px | caption2 = Estradiol valerate (top) and norethisterone enantate (bottom) | type = combo | drug_name = Estradiol valerate / norethisterone enantate | component1 = Estradiol valerate | class1 = Estrogen | component2 = Norethisterone enantate | class2 = Progestogen | tradename = Mesigyna, others | Drugs.com = | MedlinePlus = | licence_EU = | licence_US = | DailyMedID = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = Intramuscular injection | CAS_number = 99897-30-0 | CAS_supplemental = | ATCvet = | ATC_prefix = | ATC_suffix = | ATC_supplemental = | PubChem = 115350 | PubChemSubstance = | IUPHAR_ligand = | DrugBank = | ChemSpiderID = | UNII = | KEGG = | ChEBI = | ChEMBL = | synonyms = EV/NETE; HRP-102 }}Estradiol valerate/norethisterone enantate (EV/NETE), sold under the brand name Mesigyna among others, is a form of combined injectable birth control which is used to prevent pregnancy in women.[1][1][3] It contains estradiol valerate (EV), an estrogen, and norethisterone enantate (NETE), a progestin.[1][1][3] The medication is given once a month by injection into muscle.[1][1][3] EV/NETE is approved for use in at least 36 countries, and is the most widely used combined injectable contraceptive.[10][3] It is available widely throughout Latin America, in a few Asian and African countries, and in Turkey.[12][13][14] Medical usesEV/NETE is used as a combined injectable contraceptive to prevent pregnancy in women.[1][1][3] It is given by intramuscular injection once a month.[1][1][3] Available formsEV/NETE is available in the form of an oil solution containing 5 mg estradiol valerate (EV) and 50 mg norethisterone enantate (NETE).[10][1][1][3] HistoryEV/NETE, along with estradiol cypionate/medroxyprogesterone acetate (EC/MPA; code name HRP-112), was developed by the World Health Organization.[2][26] Both EV/NETE and EC/MPA became available in 1993.[3] Society and cultureGeneric namesEV/NETE is also known by its former developmental code name HRP-102.[4] Brand namesEV/NETE has been marketed under a variety of brand names including Chinese Injectable No. 3, Efectimes, Ginediol, Mesigyna, Mesilar, Meslart, Mesocept, Mesygest, Nofertyl, Nofertyl Lafrancol, Noregyna, Norestrin, Norifam, Norigynon, Nostidyn, Sexseg, and Solouna.[12][13][14][32][3][34][26][1][37] AvailabilityEV/NETE has been marketed in at least 36 countries, including Argentina, the Bahamas, Barbados, Bolivia, Brazil, Chile, Colombia, Costa Rica, the Dominican Republic, Ecuador, Egypt, El Salvador, Ghana, Grenada, Guatemala, Guyana, Haiti, Honduras, Jamaica, Kenya, Mexico, Nicaragua, Panama, Paraguay, Peru, St. Lucia, Turkey, Uruguay, Venezuela, and Zimbabwe.[5][6][7][8][9][10][11][12][13] At least 15 of the countries in which EV/NETE is registered are Caribbean states.[2] EV/NETE is the most widely used combined injectable contraceptive.[2][9] See also
References1. ^1 2 3 4 5 {{cite journal | vauthors = Sang GW | title = Pharmacodynamic effects of once-a-month combined injectable contraceptives | journal = Contraception | volume = 49 | issue = 4 | pages = 361–85 | date = April 1994 | pmid = 8013220 | doi = 10.1016/0010-7824(94)90033-7 | url = }} {{Birth control methods}}{{Hormonal contraceptives}}{{Estrogen receptor modulators}}{{Progesterone receptor modulators}}{{DEFAULTSORT:Estradiol valerate norethisterone enantate}}{{Portal bar|Pharmacy and pharmacology|Medicine}}2. ^1 2 3 4 {{cite journal | vauthors = Hall PE | title = New once-a-month injectable contraceptives, with particular reference to Cyclofem/Cyclo-Provera | journal = Int J Gynaecol Obstet | volume = 62 Suppl 1 | issue = | pages = S43–56 | date = August 1998 | pmid = 9806239 | doi = 10.1016/S0020-7292(98)00090-3 | url = }} 3. ^{{cite journal | vauthors = d'Arcangues C | title = Once-a-month injectable contraceptives | journal = World Health Forum | volume = 14 | issue = 4 | pages = 439–40 | date = 1993 | pmid = 8185807 | doi = | url = }} 4. ^{{cite journal | vauthors = Koetsawang S | title = Once-a-month injectable contraceptives: efficacy and reasons for discontinuation | journal = Contraception | volume = 49 | issue = 4 | pages = 387–98 | date = April 1994 | pmid = 8013221 | doi = 10.1016/0010-7824(94)90034-5 | url = }} 5. ^1 2 https://www.drugs.com/international/norethisterone.html 6. ^1 2 {{cite book |editor=Sweetman, Sean C. |chapter=Sex hormones and their modulators |title=Martindale: The Complete Drug Reference |edition=36th |year=2009 |page=2082 |publisher=Pharmaceutical Press |location=London|isbn=978-0-85369-840-1|url=}} 7. ^1 2 http://www.micromedexsolutions.com/micromedex2/librarian/ 8. ^1 {{cite book|author1=IARC Working Group on the Evaluation of Carcinogenic Risks to Humans|author2=International Agency for Research on Cancer|title=Hormonal Contraception and Post-menopausal Hormonal Therapy|date=1 January 1999|publisher=IARC|isbn=978-92-832-1272-0|page=65|url=https://monographs.iarc.fr/wp-content/uploads/2018/06/mono72.pdf}} 9. ^1 2 3 4 5 6 7 8 9 {{cite journal | vauthors = Bagade O, Pawar V, Patel R, Patel B, Awasarkar V, Diwate S | title = Increasing use of long-acting reversible contraception: safe, reliable, and cost-effective birth control | journal = World J Pharm Pharm Sci | volume = 3 | issue = 10 | pages = 364–392 | year = 2014 | issn = 2278-4357 | doi = | url = http://www.wjpps.com/download/article/1412071798.pdf}} 10. ^1 {{cite book|author1=Pramilla Senanayake|author2=Malcolm Potts|title=Atlas of Contraception, Second Edition|url=https://books.google.com/books?id=7dDKBQAAQBAJ&pg=PA50|date=14 April 2008|publisher=CRC Press|isbn=978-0-203-34732-4|pages=50–}} 11. ^1 2 {{cite journal | vauthors = Newton JR, D'arcangues C, Hall PE | title = A review of "once-a-month" combined injectable contraceptives | journal = J Obstet Gynaecol (Lahore) | volume = 4 Suppl 1 | issue = | pages = S1–34 | year = 1994 | pmid = 12290848 | doi = 10.3109/01443619409027641| url = }} 12. ^1 2 3 4 5 6 7 {{cite journal | vauthors = Garza-Flores J | title = Pharmacokinetics of once-a-month injectable contraceptives | journal = Contraception | volume = 49 | issue = 4 | pages = 347–59 | date = April 1994 | pmid = 8013219 | doi = 10.1016/0010-7824(94)90032-9 | url = }} 13. ^1 {{cite book|author1=IARC Working Group on the Evaluation of Carcinogenic Risks to Humans|author2=World Health Organization|author3=International Agency for Research on Cancer|title=Combined Estrogen-progestogen Contraceptives and Combined Estrogen-progestogen Menopausal Therapy|url=https://books.google.com/books?id=aGDU5xibtNgC&pg=PA431|year=2007|publisher=World Health Organization|isbn=978-92-832-1291-1|pages=431–}} 2 : Combined injectable contraceptives|World Health Organization |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。